tbuckley/cabot-search huggingface dataset:
SAT-262-Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy
Authors: Francesco Paolo Russo, Martina Gambato, Sara Piovesan, Antonietta Romano, Salvatore Lobello, sandro Panese, Veronica Paon, Bertin Tosca, Valter Vincenzi, Irene Franceschet, Caterina Pozzan, Paolo Angeli, Liliana Chemello, Franco Noventa, Giada Carolo, Annamaria Cattelan, Patrizia Burra, Alfredo Alberti
Journal: Journal of Hepatology (2019)
The aorta can act as a site of naïve CD4+ T-cell priming
Authors: Neil MacRitchie, Gianluca Grassia, Jonathan Noonan, Jennifer E Cole, Catherine E Hughes, Juliane Schroeder, Robert A Benson, Clement Cochain, Alma Zernecke, Tomasz J Guzik, Paul Garside, Claudia Monaco, Pasquale Maffia
Journal: Cardiovascular Research (2019)

Aortic adaptive immunity plays a role in atherosclerosis; however, the precise mechanisms leading to T-cell activation in the arterial wall remain poorly understood.Here, we have identified naïve T cells in the aorta of wild-type and T-cell receptor transgenic mice and we demonstrate that naïve T cells can be primed directly in the vessel wall with both kinetics and frequency of T-cell activation found to be similar to splenic and lymphoid T cells. Aortic homing of naïve T cells is regulated at least in part by the P-selectin glycosylated ligand-1 receptor. In experimental atherosclerosis the aorta supports CD4+ T-cell activation selectively driving Th1 polarization. By contrast, secondary lymphoid organs display Treg expansion.Our results demonstrate that the aorta can support T-cell priming and that naïve T cells traffic between the circulation and vessel wall. These data underpin the paradigm that local priming of T cells specific for plaque antigens contributes to atherosclerosis progression.
LBP-11-Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union?
Authors: Tullio Prestileo, Vito Di Marco, Ornella Dino, Adriana Sanfilippo, francesco Di Lorenzo, Marco Tutone, Maurizio Milesi, Camila Picchio, Antonio Craxì, Jeffrey Lazarus
Journal: Journal of Hepatology (2019)
A safe and potent anti-CD19 CAR T cell therapy
Authors: Zhitao Ying, Xue F. Huang, Xiaoyu Xiang, Yanling Liu, Xi Kang, Yuqin Song, Xiaokai Guo, Hanzhi Liu, Ning Ding, Tingting Zhang, Panpan Duan, Yufu Lin, Wen Zheng, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Yan Xie, Chen Zhang, Weiping Liu, Lijuan Deng, Shunyu Gao, Lingyan Ping, Xuejuan Wang, Nina Zhou, Junqing Zhang, Yulong Wang, Songfeng Lin, Mierzhati Mamuti, Xueyun Yu, Lizhu Fang, Shuai Wang, Haifeng Song, Guan Wang, Lindsey Jones, Jun Zhu, Si-Yi Chen
Journal: Nature Medicine (2019)
Annals Story Slam - Hero: Me or You?
Authors: Swapna Deshpande
Journal: Annals of Internal Medicine (2019)

Web Exclusives7 May 2019Annals Story Slam - Hero: Me or You?FREESwapna Deshpande, MDSwapna Deshpande, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0004 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Hero: Me or You? "Hero: Me or You?," by Dr. Swapna Deshpande (Duration 6:22)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: This article was published at Annals.org on 12 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 May 2019Volume 170, Issue 9Page: SS1 ePublished: 12 April 2019 Issue Published: 7 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
THU-374-The INCRNA H19-dervied MIR-675 promotes liver necroptosis by targeting fadd
Authors: Eithan Galun, Rona Harai-Steinfeld, Meytal Gefen, Alina Simerzin, Elina Zorde-Khvalevsky, Mila Rivkin, Ezra Ella, Tomer Friehmann, Mordeachy Gerlic, Jessica Zucman-Rossi, Stefano Caruso, Melissa Leveille, Jennifer Estall, Daniel S Goldenberg, Hilla Giladi, Zohar Bromberg
Journal: Journal of Hepatology (2019)
Abstract 15265: Meta-Analysis of Revascularization versus Medical Therapy in Coronary Artery Disease Patients With “Gray Zone” Fractional Flow Reserve Values
Authors: Hammad U Rahman, Safi U Khan, Tehseen Hammad, Edo Kaluski
Journal: Circulation (2018)

Background: The clinical benefits of percutaneous coronary revascularization (RT) in addition to medical therapy (MT) remains unclear in subjects with stable coronary artery disease (CAD) and inter...
TCTAP A-080 Effectiveness of Renal Denervation in Patients with Kidney-related Secondary Causes of Hypertension
Authors: Shu-I. Lin, Po-Lin Lin, Lawrence Yu-min Liu, Chuan Lei Chao, Wei-Ru Chiou, Feng-Ching Liao, Ying-Hsiang Lee
Journal: Journal of the American College of Cardiology (2019)
THU-015-Mutational signatures during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis
Authors: Eline Kamp, Dinjens Winand, van Marion Ronald, Doukas Michael, Verheij Joanne, Bruno Marco, Groot Koerkamp Bas, Peppelenbosch Maikel, de Vries Annemarie
Journal: Journal of Hepatology (2019)
Abstract P360: Comparison of Screening Electrocardiogram and Transthoracic Echocardiogram Abnormalities With ASCVD Risk Score Among Community Dwelling Women
Authors: Arianne Clare Agdamag, Joanne Gomez, Kumar Rajan, Emma Fleisher, Isabel Kats, Neelum Aggarwal, Lynne Braun, Rupa Sanghani, Kim A Williams, Annabelle Volgman
Journal: Circulation (2018)

Background: Increased detection of heart disease in women has been advocated nationally in recent years. The atherosclerotic cardiovascular disease (ASCVD) risk score was validated as determinant of the 10-year risk for first occurrence of nonfatal myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke in 2013. While measurement of blood pressure, glucose, and lipid levels are common in screening, the utility of non-traditional methods such as electrocardiogram (ECG) and transthoracic echocardiography (TTE) remains unknown. We examined the association of ECG and TTE abnormalities with ASCVD risk score among asymptomatic women from a community-based event. Methods: Data were gathered from 355 women (mean age 53±13 years, 24.2% African American, 59.7% Caucasian, 6.2% Hispanic, 9.9% Others) from a voluntary cardiovascular community screening event sponsored by the 2BigHearts Foundation and Rush University Medical Center in February 2007 and May 2008. Demographics, lipid panel, blood pressure, self- reported medication lists, co-morbidities, screening TTE, and ECG were obtained. The 10-year ASCVD risk score was ascertained for the cohort (283 persons, 79.7%). Chi-square testing was used to determine association of ECG and/or TTE abnormalities with ASCVD risk score. Results: The average ASCVD risk score for the entire cohort was 5.49%, with a range from 0.1-49.2. The mean ASCVD risk score was elevated in patients with either ECG or TTE abnormalities compared to those with normal findings (ECG: 7.59±9.46 vs. 4.62±5.39, p&lt;0.0014; TTE: 8.19±10.12 vs. 4.81±5.73, p&lt;0.037). The presence of both ECG and TTE abnormalities was associated with a higher mean ASCVD risk score compared to having either ECG or TTE abnormalities alone (ECG+TTE: 13.07±14.32 vs. ECG: 5.7±6.19 vs. TTE: 5.27±4.65, p&lt;0.006). Conclusion: Detection of ECG and/or TTE abnormalities are associated with elevated ASCVD risk scores in this cohort of asymptomatic women and could potentially identify patients at higher risk for cardiovascular events, and facilitate aggressive risk factor modification. Further studies are needed to confirm ECG and TTE as viable additional screening tools to traditional risk screening.
FRI-263-The VirA+EmiC project: Opt out hepatitis B and C testing of38704 patients in an urban emergency department
Authors: Terence Wong, Sam Douthwaite, Sooria Balasegaram, Basel Karo, Laura Hunter, Susanne Johanssen, Ranjababu Kulasegaram, Antonio Querol-Rubiera, Murad Ruf, Gaia Nebbia
Journal: Journal of Hepatology (2019)
THU-100-FGL2 regulates liverfibrosis progression and reversal by promoting profibrotic infiltrating macrophages maintenance
Authors: Ran Tao, Wei Yuan, Fang Xiao, meiqi liu, Hongwu Wang, Di Wu, Peng Wang, Jiaquan Huang, Xiaoping Luo, Xiaoyang Wan, Qin Ning
Journal: Journal of Hepatology (2019)
SAT-087-Screening endoscopy in patients with advanced chronic liver disease beyond portal hypertension: Higher prevalence of upper gastrointestinal neoplasia in comparison to a healthy screening population
Authors: Rui Morais, Margarida Marques, Rui Gaspar, Rosa Alves, Joel Silva, Emanuel Dias, João Antunes, Pedro Pereira, Susana Lopes, Hélder Cardoso, Rodrigo Liberal, Guilherme Macedo
Journal: Journal of Hepatology (2019)
First evidence of a food poisoning outbreak due to staphylococcal enterotoxin type E, France, 2009
Authors: A Ostyn, M L De Buyser, F Guillier, J Groult, B Félix, S Salah, G Delmas, J A Hennekinne
Journal: Eurosurveillance (2010)

At the end of 2009, six food poisoning outbreaks caused by staphylococci were reported in France. Soft cheese made from unpasteurized milk was found to be the common source of the outbreaks. Staphylococcal enterotoxin type E was identified and quantified in the cheese using both official and confirmatory methods of the European Union Reference Laboratory (EU-RL). To our knowledge, this is the first report of food poisoning outbreaks caused by staphylococcal enterotoxin type E in France.
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension
Authors: Kelly M. Chin, Lewis J. Rubin, Richard Channick, Lilla Di Scala, Sean Gaine, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene M. Lang, Vallerie V. McLaughlin, Ralph Preiss, Gérald Simonneau, Olivier Sitbon, Victor F. Tapson
Journal: Circulation (2019)

NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH guidelines. However, data supporting the use of NT-proBNP risk thresholds in assessing prognosis in PAH are limited. The GRIPHON trial (Prostacyclin [PGI2] Receptor Agonist In Pulmonary Arterial Hypertension) provides an opportunity to assess the prognostic value of NT-proBNP thresholds in a controlled clinical trial and to evaluate the response to selexipag according to these thresholds.The event-driven GRIPHON trial randomly assigned patients to selexipag or placebo. NT-proBNP was measured at regular intervals in GRIPHON. Here, patients were categorized post hoc into low, medium, and high NT-proBNP subgroups according to 2 independent sets of thresholds: (1) baseline tertiles: <271 ng/L; 271 to 1165 ng/L; >1165 ng/L; and (2) 2015 European Society of Cardiology/European Respiratory Society guidelines cutoffs: <300 ng/L; 300 to 1400 ng/L; >1400 ng/L. Hazard ratios (selexipag versus placebo) with 95% CIs were calculated for the primary end point (composite morbidity/mortality events) by NT-proBNP category at baseline using Cox proportional-hazards models, and at any time during the exposure period using a time-dependent Cox model.With both thresholds, baseline and follow-up NT-proBNP categories were highly prognostic for future morbidity/mortality events during the study ( P<0.0001). In the time-dependent analysis, the risk of experiencing a morbidity/mortality event was 92% and 83% lower in selexipag-treated patients with a low and medium NT-proBNP level, and 90% and 56% lower in placebo-treated patients with a low and medium NT-proBNP level, in comparison with patients with a high NT-proBNP level. Selexipag reduced the risk of morbidity/mortality events across all 3 NT-proBNP categories in both the baseline and time-dependent analyses, with a more pronounced treatment benefit of selexipag seen in the medium and low NT-proBNP subgroups (interaction P values 0.20 and 0.007 in the baseline and time-dependent analyses).These analyses further establish the prognostic relevance of NT-proBNP levels in PAH and provide first evidence for the association of NT-proBNP level and treatment response. Using 2 similar sets of thresholds, these analyses support the relevance of the low, medium, and high NT-proBNP categories as part of the multiparametric risk assessment approach outlined in the European Society of Cardiology/European Respiratory Society guidelines for the management of PAH patients.URL: https://www.clinicaltrials.gov . Unique identifier: NCT01106014.
Abstract 18136: The Tale of Two Chambers : Late Diagnosis of a Young Condition
Authors: Aeshita Dwivedi, Catherine Weinberg, Albert Jung
Journal: Circulation (2016)

A 41-year-old female with a small, asymptomatic ventricular septal defect (VSD), obesity, and asthma presented with 2 months of dyspnea on exertion and palpitations. Her symptoms were initially tho...
SAT-440-Molecular fingerprint of T cell-mediated and antibody-mediated rejection after human liver transplantation
Authors: Anne Höfer, Danny Jonigk, Björn Hartleben, Robert Geffers, Murielle Verboom, Michael Hallensleben, Stefan Hübscher, Michael P. Manns, Elmar Jaeckel, Richard Taubert
Journal: Journal of Hepatology (2019)
The ALT-70 cellulitis model maintains predictive value at 24 and 48 hours after presentation
Authors: Sean Singer, David G. Li, Nicole Gunasekera, Jean-Phillip Okhovat, Priyanka Vedak, Christina Weng, Jeffrey Cohen, Cara Joyce, Adam Raff, Daniela Kroshinsky, Arash Mostaghimi
Journal: Journal of the American Academy of Dermatology (2019)
SAT-182-Full length deep sequencing of South African hepatitis B virus isolates reveals increased viral diversity and X-gene deletions in hepatocellular carcinoma patients
Authors: Tongai G Maponga, Anna Mcnaughton, Mariateresa de Cesare, M Azim Ansari, Camilla LC Ip, Richard Glashoff, Wolfgang Preiser, David Bonsall, Monique I Andersson, Philippa Matthews
Journal: Journal of Hepatology (2019)
Abstract 3666: Remaining Lifetime Risks for Cardiovascular Disease Death by Risk Factor Burden at Selected Ages in Black and White Men and Women
Authors: Jarett D Berry, Daniel B Garside, Xuan Cai, Alan R Dyer, Donald M Lloyd-Jones
Journal: Circulation (2007)

BACKGROUND: Although the effect of risk factor (RF) burden at age 50 years has been reported, the effect of RF burden measured at other ages on lifetime risk for cardiovascular diseases (CVD) is unknown and no data are available for non-whites. METHODS: Using limited access data from the National Heart Lung and Blood Institute, we pooled participants from the Framingham Heart Study, the Framingham Offspring Study, the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, and the Chicago Heart Association Detection Project in Industry with RFs measured at or near ages 45, 55, and 65 years for blacks and whites separately in sex-stratified analyses. Blood pressure and cholesterol levels, smoking, and diabetes status were used to stratify the pooled cohort into 5 risk strata. Lifetime risks for CVD events to 85 years of age were estimated for men and women, with death free of CVD as a competing event. RESULTS: We included 21,534 men (15.7% black) and 24,063 women (9.3% black) who were followed for 651,144 person-years. With more adverse levels of single risk factors, lifetime risks were greater for both men and women in both races. Compared with white participants with ≥2 major RFs, those with all optimal RF levels had substantially lower lifetime risks (see Table ). There was a similar pattern of results observed in blacks for lifetime risks for CVD death. Additional analyses of the endpoints of fatal/non-fatal coronary heart disease and fatal/non-fatal stroke revealed a similar pattern of results. CONCLUSIONS: Remaining lifetime risks for CVD are dramatically higher with greater RF burden at all ages studied. The absence of established RFs is associated with very low remaining lifetime risk for CVD, particularly for men and women at age 65 years.
Physical activity promotion in Australian physiotherapy practice: how do physiotherapists promote physical activity and what factors influence promotion? (PhD Academy Award)
Authors: Brea Kunstler
Journal: British Journal of Sports Medicine (2019)

My PhD comprised studies that identified: (1) the efficacy of physiotherapist-led physical activity (PA) interventions; (2) the behaviour change techniques (BCTs), or individual strategies, Australian physiotherapists use to promote PA to improve general health (non-treatment physical activity [NTPA]) and (3) the factors influencing their decision to promote NTPA.1–5 

Physiotherapists are expected to promote NTPA to increase the PA levels of patients to improve general health.6 It was important to establish if private practice and outpatient physiotherapists can successfully promote NTPA and the difficulties they face.

I completed two systematic reviews that found physiotherapist-led NTPA interventions can increase patient PA levels in the short term only.1 Additionally, I found that physiotherapists use fewer BCTs when promoting NTPA in clinical compared with experimental settings,2 suggesting that physiotherapists might use few BCTs to change PA behaviour in practice. I designed a survey and an interview study to explain these findings. …
T cell anergy in perinatal mice is promoted by T reg cells and prevented by IL-33
Authors: Jonatan Tuncel, Christophe Benoist, Diane Mathis
Journal: The Journal of Experimental Medicine (2019)

Perinatal T cells broadly access nonlymphoid tissues, where they are exposed to sessile tissue antigens. To probe the outcome of such encounters, we examined the defective elimination of self-reactive clones in Aire-deficient mice. Nonlymphoid tissues were sequentially seeded by distinct waves of CD4+ T cells. Early arrivers were mostly Foxp3+ regulatory T (T reg) cells and metabolically active, highly proliferative conventional T cells (T conv cells). T conv cells had unusually high expression of PD-1 and the IL-33 receptor ST2. As T conv cells accumulated in the tissue, they gradually lost expression of ST2, ceased to proliferate, and acquired an anergic phenotype. The transition from effector to anergic state was substantially faster in ST2-deficient perinates, whereas it was abrogated in IL-33–treated mice. A similar dampening of anergy occurred after depletion of perinatal T reg cells. Attenuation of anergy through PD-1 blockade or IL-33 administration promoted the immediate breakdown of tolerance and onset of multiorgan autoimmunity. Hence, regulating IL-33 availability may be critical in maintaining T cell anergy.
The role of exosomal noncoding RNAs in cancer
Authors: Yan Xie, Wei Dang, Siwei Zhang, Wenxing Yue, Li Yang, Xingyu Zhai, Qijia Yan, Jianhong Lu
Journal: Molecular Cancer (2019)

Extracellular vesicles (EVs) membranes enclose nanosized vesicles with a size range of 30-150 nm and are plentiful in our body in both physiological and pathological conditions. Exosomes, a type of EV, are important mediators of intracellular communication among tumor cells, immune cells, and stromal cells. They can shuttle bioactive molecules, such as proteins, lipids, RNA, and DNA; however, the precise function of EVs remains largely unknown. In recent years, tumor-associated cargo in exosomes has been a hot topic in research, especially with respect to noncoding RNAs (ncRNAs). Herein, we review the role of exosomal ncRNAs, including miRNAs and long noncoding RNAs, in tumor biological processes. Clinically, exosomal ncRNAs may eventually become novel biomarkers and therapeutic targets in cancer progression.
In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration
Authors: Thomas Sécher, Emilie Dalonneau, Marion Ferreira, Christelle Parent, Nicolas Azzopardi, Gilles Paintaud, Mustapha Si-Tahar, Nathalie Heuzé-Vourc'h
Journal: Journal of Controlled Release (2019)
Experience Is Crucial in Off-Pump Coronary Artery Bypass Grafting
Authors: John D. Puskas, Mario Gaudino, David P. Taggart
Journal: Circulation (2019)

Article, see p 1865 T he relative merits of off-pump versus on-pump coronary artery bypass grafting (CABG) have been debated in the surgical literature for >25 years.Between 2003 and 2008, 3 large prospective randomized controlled clinical trials (comprising a total of 9494 patients) were initiated: the ROOBY trial (Randomized On/Off Bypass), the CORONARY trial (CABG Off or On Pump Revascularization Study), and the GOPCABE trial (German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients).In this issue of Circulation, Diegeler et al 1 report the outcome of the GOPCABE trial, the last of the 3 studies to reach the 5-year mark.In GOPCABE, at 5 years, no difference in survival or the composite of death, myocardial infarction, and repeat revascularization was found among the 2539 patients, aged ≥75 years, randomly assigned to one or the other technique.The results are concordant with the largest of the 3 trials (CORONARY), 2 but are in contrast with those of ROOBY. 3 CORONARY set a high bar for surgeon qualification, requiring surgeons to have performed at least 100 off-pump coronary artery bypass grafting (OPCAB) procedures before the study.GOPCABE included only very experienced operators (the median pretrial OPCAB experience was 322 cases), whereas ROOBY had a much lower experience requirement (50 cases).The mean number of grafts per patient was very similar in all 3 trials (OPCAB versus onpump coronary artery bypass grafting [ONCAB] 2.9 versus 3.0 in ROOBY, 3.0 versus 3.2 in CORONARY, and 2.7 versus 2.8 in GOPCABE), although the differences reached statistical significance.Although the rate of incomplete revascularization was slightly higher in the OPCAB group in all 3 trials (OPCAB versus ONCAB 13.2 versus 9.1 in ROOBY, 11.8 versus 10.0 in CORONARY, and 34.0 versus 29.3 in GOPCABE), the difference in the completeness of revascularization between the 2 arms was not associated with survival in a recent meta-analysis. 4 The critical role of surgeons' experience in OPCAB has been repeatedly emphasized by experts in the field and recently demonstrated using registry data and a meta-analytic approach.In an analysis of the Nationwide Inpatient Sample including >2 million patients, Benedetto et al 5 reported that OPCAB reduces operative mortality when performed by surgeons in high-volume OPCAB centers but is associated with increased operative risk in the hands of low-volume surgeons and in-low volume centers.In surgical trials, a lack of experience and comfort with the experimental technique will typically result in a high crossover rate to the control arm.In fact, the crossover rate from the OPCAB group was 7.9% and 9.7% in CORONARY and GOPCABE, respectively, versus 12.4% in ROOBY.In the largest randomized controlled trial meta-analysis of OPCAB versus ONCAB to date (104 trials, 30 915 patients), we showed that a difference in survival in favor of ONCAB is found only in the studies with a crossover rate ≥10%, a rate that may be con-
Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80
Authors: O. Leleu, M.-A. Auquier, B. Chauffert, P. Berna, V. Petigny, A. Ait Addi, D. Basille, V. Jounieaux
Journal: Annals of Oncology (2019)

Background: Lung cancer is the leading cause of cancer death worldwide. Two large randomized controlled trials (NLST,NELSON) founded a significant decrease in lung cancer mortality with an annual low dose CT screening among selected current or former smockers.While being now recommended in many countries, the French National Authority for Health claimed that conditions were not sufficient for implementation of such a screening program in France. The aims of our study were to assess the feasibility and effectiveness of a lung cancer screening pilot program with LD CT scan in a French department.